We are live on ! Find out more
CPRX icon

Catalyst Pharmaceutical
CPRX

105 hedge funds and large institutions have $219M invested in Catalyst Pharmaceutical in 2017 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 30 increasing their positions, 21 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

192% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 13

144% more capital invested

Capital invested by funds: $89.7M → $219M (+$129M)

43% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 21

31% more funds holding

Funds holding: 80 → 105 (+25)

12.6% more ownership

Funds ownership: 42.11% → 54.7% (+13%)

16% less call options, than puts

Call options by funds: $108K | Put options by funds: $128K

Holders
105
Holders Change
+25
Holders Change %
+31.25%
% of All Funds
2.38%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
38
Increased
30
Reduced
21
Closed
13
Calls
$108K
Puts
$128K
Net Calls
-$20K
Net Calls Change
+$27K

Top Buyers

1
CCM
Consonance Capital Management
New York
+$13.6M
2
GPP
Great Point Partners
Connecticut
+$12.6M
3
Millennium Management
Millennium Management
New York
+$6.83M
4
EA
Emerald Advisers
Pennsylvania
+$4.53M
5
DCM
Driehaus Capital Management
Illinois
+$4.07M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$2.46M
2
CS
Candriam SCA
Luxembourg
-$1.41M
3
AL
AJO LP
Pennsylvania
-$1.22M
4
GCP
GSA Capital Partners
United Kingdom
-$1.21M
5
JP Morgan Chase
JP Morgan Chase
New York
-$273K
Name Holding Trade Value Shares
Change 		Change in
Stake
AL
26
AJO LP
Pennsylvania
$1.55M -$1.22M -369,604 -48%
DMK
27
David M. Knott
$1.49M +$49.6K +15,000 +4%
Goldman Sachs
28
Goldman Sachs
New York
$1.43M +$1.06M +320,810 +704%
Ameriprise
29
Ameriprise
Minnesota
$1.34M +$1.13M +341,956 New
AQR Capital Management
30
AQR Capital Management
Connecticut
$1.32M -$53K -16,048 -5%
Fidelity Investments
31
Fidelity Investments
Massachusetts
$1.17M – – –
CM
32
Crestline Management
Texas
$1.04M +$146K +44,093 +20%
PPA
33
Parametric Portfolio Associates
Washington
$1.02M +$863K +261,325 New
TCM
34
Tanaka Capital Management
New York
$1M +$51.3K +15,515 +6%
EGI
35
EAM Global Investors
California
$984K +$831K +251,647 New
Squarepoint
36
Squarepoint
New York
$730K +$363K +109,743 +143%
TCIM
37
TIAA CREF Investment Management
New York
$717K -$25.7K -7,786 -4%
OAM
38
Oxford Asset Management
United Kingdom
$696K +$123K +37,138 +27%
ARTA
39
A.R.T. Advisors
New York
$686K +$324K +98,157 +127%
MWNA
40
Marshall Wace North America
New York
$661K +$558K +168,974 New
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$647K -$19.7K -5,957 -3%
SO
42
STRS Ohio
Ohio
$637K +$539K +163,000 New
Citadel Advisors
43
Citadel Advisors
Florida
$602K +$475K +143,697 +1,418%
Charles Schwab
44
Charles Schwab
California
$582K +$93.2K +28,204 +23%
TA
45
Teachers Advisors
New York
$495K – – –
Prudential Financial
46
Prudential Financial
New Jersey
$469K +$397K +120,170 New
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$441K -$15.9K -4,822 -4%
AA
48
ALPS Advisors
Colorado
$435K +$367K +111,179 New
BIM
49
Bogle Investment Management
Massachusetts
$424K +$359K +108,649 New
D.E. Shaw & Co
50
D.E. Shaw & Co
New York
$411K +$347K +105,148 New
1
2
3 4 5

CPRX Hedge Fund Activity: Q4 2017 in Review

105 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2017, worth a combined $219M — up 144% from $89.7M a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new CPRX positions and 13 closed out — a net gain of 25 holders — while 30 added to existing stakes and 21 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $13.6M. The largest seller was Avoro Capital Advisors, cutting an estimated $2.46M.

  • 105 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2017, up from 80 in Q3 2017.
  • Funds reported $219M of Catalyst Pharmaceutical stock for Q4 2017, up 144% quarter-over-quarter.
  • 38 funds opened new Catalyst Pharmaceutical positions in Q4 2017 and 13 closed out, a net change of +25 holders.
  • The largest Catalyst Pharmaceutical buyer in Q4 2017 was Consonance Capital Management, an estimated $13.6M added.
  • The largest Catalyst Pharmaceutical seller in Q4 2017 was Avoro Capital Advisors, an estimated $2.46M sold.

Based on aggregated 13F filings for Q4 2017.